Assessment and Utilization of Patient-Reported Outcomes Measures to Improve Cardiovascular Disease Prevention

Phoebe A Finneran, BS^{a-c}, Tinamarie Sanborn, RN^a, Xiao Guo^a, Kate C Traynor, RN, MS^a,
Michael R. Jaff, DO^d, Pradeep Natarajan, MD, MMSc^{a-c,e*}

^a Cardiovascular Disease Prevention Center, Massachusetts General Hospital, Boston, MA 02114

^b Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge,
MA 02142

^c Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114

^d Newton-Wellesley Hospital

^e Department of Medicine, Harvard Medical School, Boston, MA 02115

* Corresponding author

SOURCES OF FUNDING

This work was supported by Massachusetts General Hospital. P.N. is supported by a grant from the National Heart Lung and Blood Institute (K08 HL140203) and Hassenfeld Scholar award from the Massachusetts General Hospital.

Please address correspondence to:

Pradeep Natarajan, MD, MMSc

Mail: 185 Cambridge Street, CPZN 3.184, Boston, MA 02114

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

PROMs in Cardiovascular Disease Prevention

1 Email: pnatarajan@mgh.harvard.edu

2 Office: 617-724-3526

3 Fax: 617-726-2203

4 Twitter: @pnatarajanmd

5

6

Abstract

Background

The American Heart Association's Life's Simple 7 (LS7) consist of clinical factors and health-related behaviors associated with cardiovascular health. The prevalence of these health factors among patients seeking specialized cardiovascular care is unknown. We sought to quantify patient-reported cardiovascular risk among those seeking specialized cardiovascular care and implement tailored quality improvement interventions.

Methods and Results

Patients cared for by cardiovascular specialists at an academic medical center were surveyed with a modified LS7. We compared the prevalence of optimal health factors by atherosclerotic cardiovascular disease (ASCVD) status. Recent smokers or patients with ASCVD reporting non-adherence to antiplatelets/statins were contacted.

Surveys for 5,950 patients were collected during 2014 to 2016. The mean (SD) age was 64 (15) years, 2613 (44%) were women, and 3478 (58%) had ASCVD. Only 34 (0.6 %) achieved ideal status for all 7 factors, which did not differ by ASCVD status ($P=0.48$). Of 404 (6.8%) reporting recent smoking, 94/404 (23.3%) were successfully contacted, and 71/404 (17.6%) accepted support. Among those with ASCVD, 84 (2.4%) reported not taking a statin or antiplatelet without contraindications.

PROMs in Cardiovascular Disease Prevention

1 **Conclusions**

- 2 The prevalence of optimal health factors, including health-related behaviors, among patients
- 3 cared for by cardiovascular specialists remains low. Assessment of patient-reported outcomes
- 4 facilitates scalable interventions to improve cardiovascular disease prevention.

1 Introduction

2 Cardiovascular diseases (CVD) remain the leading cause of death in the US and
 3 worldwide¹⁻³. In the US, healthcare spending accounts for approximately 17% of the US
 4 economy, and CVD accounts for the largest single fraction of these expenditures⁴. The American
 5 Heart Association (AHA) defined 7 health-related behaviors and quantitative clinical variables
 6 deemed Life's Simple 7 (LS7), related to smoking, weight, physical activity, diet, cholesterol
 7 levels, blood pressure, and fasting glucose that contribute to ideal cardiovascular health⁵. In
 8 2010, the AHA outlined the promotion of cardiovascular health, through optimization of the
 9 LS7, as a key 2020 Impact Goal to reduce cardiovascular and stroke death⁵. These health factors
 10 are associated with greater life expectancy, decreased incidence of CVD, increased health-related
 11 quality-of-life, and lower individual healthcare costs⁵. However, the prevalence of ideal health
 12 factors generally among American adults is extremely low, with <1% achieving ideal status
 13 across all 7 health factors⁶⁻¹¹. In a setting where patients are seeking care with cardiovascular and
 14 cerebrovascular specialists, the prevalence of these factors are unknown.

15
 16 Clinical screening for metabolic risk factors and promoting strategies for behavior modification
 17 in concert with pharmacotherapy where appropriate, are key strategies for cardiovascular disease
 18 prevention^{12,13}. Cardiovascular disease specialists are uniquely positioned to systematically
 19 assess modifiable risk factors via patient-reported outcomes and intervene to improve clinical
 20 outcomes¹⁴. In epidemiologic cohorts, a high prevalence of ideal health-related behaviors and
 21 optimally controlled risk factors are associated with reduced future cardiovascular disease risk
 22 but <3% are optimal for all factors¹⁵⁻¹⁷. The prevalence of self-reported cardiovascular health-

PROMs in Cardiovascular Disease Prevention

1 related behaviors, are poorly defined in the health-care setting, let alone outpatient practices
2 addressing cardiovascular diseases.
3
4 We conducted a quality improvement initiative within a single large academic medical center to
5 determine the prevalence of optimal and suboptimal health factors amongst patients seeking care
6 from cardiovascular disease specialists, and developed interventions to address suboptimal
7 health-related behaviors. We observed that, even among patients cared for by cardiovascular
8 disease specialists, optimal status across ideal health factors and behaviors is very low. We also
9 demonstrate a framework for using patient-reported outcomes to address high risk cardiovascular
10 health-related behaviors.

Methods

We consecutively approached patients cared for by cardiovascular disease specialists at the Massachusetts General Hospital (MGH), a large academic medical center, in outpatient clinical settings. Outpatient clinics included the women’s heart health program, preventive cardiology, interventional cardiology, vascular surgery, vascular medicine, and stroke neurology. Patients were surveyed between May 2014 and March 2016. All patients seeking care were approached and those agreeable to fill out the questionnaire in English participated. This project was a quality improvement initiative and thereby exempt from oversight by the Partners Healthcare Institutional Review Board.

An electronic tablet-based survey (“My Health Check”) was developed using Tonic’s Patient Reported Outcomes platform (<https://tonicforhealth.com/patientreportedoutcomes>). In addition to the American Heart Association’s LS7 (S1 Table), we assessed for the presence of cardiovascular diseases and adherence to key medications (S1 Text). Patients were provided an electronic tablet to fill out the survey while waiting for physicians in waiting rooms or exam rooms.

To maximize accuracy of self-report of cholesterol, glucose, and blood pressure values, patients were provided a paper copy of their most recent lab values and blood pressure measurements; patients reconciled this report with values potentially ascertained in other settings (e.g. laboratory tests performed at another facility, home blood pressure measurements, etc). A personalized report was displayed on the iPad, printed for the patient, and uploaded into the electronic health

PROMs in Cardiovascular Disease Prevention

record (S1 Fig, S1 Text). Ideal, intermediate, or poor status for each of the ascertained health factors are defined in S1 Table.

“High risk” was defined as the presence of current smoking (active or quit less than one month ago), or the presence of atherosclerotic cardiovascular disease (ASCVD) but reported non-adherence to an antiplatelet or a statin. Survey results for high risk patients were imported weekly into a high risk patient registry in REDCap (<https://www.project-redcap.org>). A nurse then reviewed these patients’ charts to categorize high risk behaviors and document interventions in the patient’s REDCap form.

The process for identifying high risk patients was reviewed with clinic managers and medical directors, who encouraged physicians to discuss smoking cessation with current smokers at their office visit. The nurse called current smokers and used motivational interviewing¹⁸ to encourage tobacco abstinence. Interest scales, confidence scales, and stages of change were determined from telephone interview. Both interest and confidence were scored on 0-10 Likert scales (0 = Not important at all / Not confident at all; 10 = Most important goal / 100% Confidence) in increments of 2. Stage of change was categorized as pre-contemplation, contemplation, preparation, action, or maintenance^{19,20}. Patients who could not be reached were scored based on chart review of documented smoking cessation counseling while admitted at MGH. Patients who accepted support were then referred to various local and online tobacco cessation resources, and the phone intervention and referral outcome were documented in the patient’s chart.

PROMs in Cardiovascular Disease Prevention

For patients indicating they had ASCVD but were not on an antiplatelet or a statin, their charts were reviewed to confirm history of disease, medication prescription, and allergy or contraindication. High risk intervention category (prevalent ASCVD on Aspirin not statin, prevalent ASCVD on statin not Aspirin, or prevalent ASCVD not on Aspirin or statin) was recorded in the patient's REDCap form. Patients with a documented reason for not being on the medication were categorized as Not Applicable, and then further categorized as: Intolerance documented, Taking a different antiplatelet, Statin contraindicated, ASA contraindicated, Started medication at office visit, or No history ASCVD. For patients without a prescription, the pharmacy and/or physician was contacted. Patients who were already prescribed the medication with no documented contraindications were called. If patients were taking a medication but unaware that this was a statin (or rarely, aspirin) they were marked as having a 'Knowledge deficit.' The patient's cardiovascular disease specialist and primary care provider were notified of the findings via email. Eligible patients were offered referral to the Cardiovascular Prevention Center for a risk reduction visit.

The primary outcome was number of ideal factors for all patients. We compared the proportion suboptimal for each LS7 factor in patients with and without ASCVD using a two-sample proportion t-test. We also performed similar analyses comparing those with and without diabetes mellitus. In secondary analyses, we calculated a continuous LS7 score of 0-14, with each factor scored as 0, 1, or 2 for poor, intermediate, or ideal, respectively. We compared the continuous LS7 score between those with and without ASCVD using linear regression; we also pursued adjustment for age, sex, ethnicity, and clinic. Statistical significance was assigned at $\alpha = 0.05$. In sensitivity analyses, among only participants who fully completed the survey,

PROMs in Cardiovascular Disease Prevention

- 1 we evaluated the number of ideal factors in these patients, and compared LS7 score between
- 2 those with and without ASCVD using linear regression.
- 3
- 4 The data was analyzed using the statistical software, R, version 3.4.2 (R Foundation for
- 5 Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>).

Results

5,950 patients under the care of cardiovascular or cerebrovascular specialists at MGH were surveyed in the outpatient setting using electronic tablets. Patients were distributed among MGH Cardiology (3,618, 60.8 %), Stroke (902, 15.2%), and Vascular Surgery 1,430 (24.0 %). Baseline characteristics of surveyed participants are provided in Table 1. The mean (standard deviation) age was 64 (15) years, 2,613 (44%) were female, and 4,836 (81%) were white. 58.5% (3,478) indicated the presence of ASCVD; of these 911 (26.2%) reported prior myocardial infarction. Survey completion rate was 42% (2,526) for LS7 questions.

Among all 5,950 surveyed patients, only 34 (0.6%) achieved ideal status for all 7 factors (Fig 1). 743 (12.6%) achieved ideal status for at least 5 of 7 factors. 2,600 (43.7%) achieved ideal status for 2 or fewer of 7 factors. 730 (12.3%) were ideal for all 3 health-related behaviors (i.e., diet, physical activity, and smoking). While 5,076 (85%) were not smoking, 4,350 (73%) and 2,907 (49%) were not ideal for diet and physical activity, respectively; in fact, 2,439 (41%) and 1,775 (30%) had poor status for diet and physical activity, respectively (Table 2). Additionally, 151 (2.5%) were ideal for all 4 quantitative cardiovascular risk factors. Among all LS7 components, diet had the highest prevalence of poor status responses 2439 (41%).

When weighted by poor (0), intermediate (1), or ideal (2) status across the 7 factors (maximum score 14), the mean (SD) score was 7.2 (2.9) (S2 Fig). Survey completion was a strong predictor of this score (Beta = 2.4, SE = 0.06, P value <0.001). Those who completed the survey fully tended to be mostly older (mean 66 versus 64 years; P value <0.001), white (84% versus 79%; P

PROMs in Cardiovascular Disease Prevention

value <0.001), and with ASCVD (64% versus 54%; P value <0.001) (S2 Table). When only evaluating the 2,526 (42%) who fully completed the survey, the mean (SD) score was 8.9 (2.3) and only 30 (1.2%) were ideal across all 7 health-related behaviors (S3 Fig). In a multivariable model of demographics and prevalent cardiovascular diseases, diabetes mellitus and actively smoking were independently associated with a lower LS7 score; male sex, cardiology clinic, and stroke clinic were associated with a higher LS7 score (S3 Table).

Those with ASCVD had a similar proportion of individuals ideal for at least 5 of 7 health-related behaviors (444 (14.6%)) compared to those without ASCVD (298 (15.5%)) (P value = 0.49). Mean (standard deviation) LS7 score for patients with ASCVD was 7.5 (2.7) and 7.5 (2.6) for those without; when accounting for age, sex, ethnicity, and clinic, these scores were not significantly different (P value = 0.48) (S4 Fig). While a significantly higher proportion of individuals with ASCVD were ideal for LDL cholesterol, this was offset by higher proportion of suboptimal glucose, and suboptimal diet persisted at similar rates for those with and without ASCVD (S4 Table, Fig 2). Additionally, among those with ASCVD, 12% reported current smoking compared to 8% among those without ASCVD (P value <0.001). Among patients who fully completed the LS7 questions, we still did not observe a significant difference in LS7 score by ASCVD presence (S5 Fig). Similar results were found for those with diabetes mellitus compared to those without (S5 Table).

PROMs in Cardiovascular Disease Prevention

Of those surveyed, 6% (389) indicated they were either active smokers or quit less than a month ago (Table 1). Fifteen additional smokers were identified when contacted about another risk factor. Of the smokers, the mean (standard deviation) age was 66 (15) years, 165 (40.8%) were female, and 273 (67.8%) had prevalent ASCVD. Out of 404 recent smokers, 94 (23%) were successfully counseled by phone, and 71 (18%) ultimately accepted additional support. Of those who accepted support, most accepted the nurse's contact information (84%) for potential follow-up counseling and 38% accepted education materials regarding smoking cessation (S6 Table).

All 404 self-reported recent smokers' charts were separately reviewed, and 289 were scored for three tobacco cessation readiness indices: interest, stage of change, and confidence. While 54% previously indicated in clinic notes high interest in smoking cessation (10 of 10 interest), most were in the pre-contemplative (35%) or contemplative (24%) stages of quitting. Nevertheless, 49% had high confidence (at least 8 of 10 confidence) in tobacco cessation (Table 3). Overall, the distributions were bi-modal with 26% displaying low interest (≤ 2 of 10) and 37% displaying low confidence (≤ 4 of 10). Of the smokers who were successfully contacted, mean confidence and interest scores were similar (P value = 0.27 and 0.06, respectively) when tobacco cessation counseling was provided versus clinician chart documentation (S7 Table).

We identified patients with ASCVD who reported they were not taking a statin or an antiplatelet, and reviewed their charts to identify explanations for non-adherence. Of those with ASCVD, 868 (25%) reported not taking a statin or antiplatelet, or both. Based on chart review and contact with physician or pharmacy, non-adherence without contraindication was confirmed

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

PROMs in Cardiovascular Disease Prevention

1 in 84 of 868 (10.1%), representing 2.4% patients with ASCVD (Table 4). Cardiovascular
2 specialists and primary care doctors were contacted for these patients.

3

4

5

Discussion

Through the assessment of patient-reported outcome measures of cardiovascular health factors and behaviors, we highlight gaps in cardiovascular disease preventive care for patients cared for by specialists at a tertiary academic medical center as well as strategies to begin to address these gaps. Only 1 in 100 patients seeking specialty cardiovascular care are optimal for the AHA's LS7 and only 1 in 8 are optimal for health-related behaviors; even after ASCVD is manifest, with the exception of improved LDL cholesterol values, the prevalence of optimal LS7 factors remains largely similar. For key high-risk behaviors, recent smoking, non-adherence to guideline-directed medicines, and metabolic syndrome with poor diet and physical activity, we implemented scalable quality improvement interventions.

Our findings may have important implications for ASCVD risk mitigation at the individual- and population-level. First, despite receiving care from cardiovascular or cerebrovascular specialists, the prevalence of ideal status across all health-related factors and behaviors is similar to reports in the general population⁶⁻¹⁰. Optimal status for these factors is associated with reduced cardiovascular disease risk in a dose-dependent manner²¹. As such, the American College of Cardiology and American Heart Association recommend the promotion of heart-healthy nutrition and physical activity behaviors for all adults to reduce cardiovascular disease risk²². Given the marked differences only in ideal LDL cholesterol values, emphasis in preventive cardiovascular medicine remains largely focused on pharmacotherapy-driven LDL cholesterol reduction. While this remains a highly effective strategy to reduce cardiovascular disease risk, sizeable persistent cardiovascular disease risks persist^{23,24}. Our study highlights that persistent high risk health-

PROMs in Cardiovascular Disease Prevention

related behaviors are highly prevalent, even when clinical ASCVD is recognized by patients and cardiovascular specialists.

Second, assessing patient-reported outcome measures not only provides a means for refining cardiovascular disease risk, but an opportunity to mitigate risk. Prior work has shown that cardiovascular risk communication to patients promotes the improvement of quantifiable risk factors^{25,26}. Therefore, we provided a patient-facing report with an assessment of responses as well as advice tailored to survey responses. We also used patient-reported medication adherence to reconcile discrepancies with physicians and pharmacists. For example, approximately 1 in 10 patients with ASCVD reported not taking a statin or antiplatelet without contraindications in our study, which is similar to adherence rates reported in other clinical settings^{27,28}. A recent study within the Veterans Affairs Health System closely linked statin non-adherence to future risk of death²⁹. A recent systematic review concluded that the intensification of patient care interventions within healthcare systems can improve the short- and long-term adherence of cardiovascular disease risk-reducing medications³⁰. Here, we leverage patient-reported non-adherence as an opportunity for additional patient, physician, and pharmacist engagement where necessary to promote adherence.

Third, scalable behavioral modification for cardiovascular disease prevention may be achievable through remote proactive strategies. Referral for telephone tobacco cessation counseling is associated with higher smoking cessation rates compared to standard take-home materials³¹⁻³³. When patients call such services, efficacy is improved with proactive (i.e., additional outgoing calls after an index incoming call) versus reactive (i.e., only counseling from incoming calls)

PROMs in Cardiovascular Disease Prevention

counseling³⁴. However, by leveraging systematic collection of patient-reported outcome measures, we are able to provide proactive counseling. Our data shows that we are able to contact a group of individuals unlikely to seek tobacco cessation counseling.

While our study has several strengths, there are important limitations. First, to maximally evaluate the value of patient-reported outcome measures, patients were asked to input medical history and quantitative metrics, including blood pressure, lipids, and glucose. To minimize errors, when laboratory values were recently measured within our health system, these values were provided to patients. Potential medical history misclassification does not influence the calculation or interpretation of the LS7 score. Second, while we did not observe differences in the LS7 score between those with and without ASCVD, those with ASCVD may have had poorer scores antecedent to ASCVD diagnosis. Unfortunately, even among those who participate in cardiac rehabilitation, a minority maintain an exercise regimen as long as six months later^{35,36}. Longitudinal surveying is required to characterize the impact of ASCVD diagnosis on health-related behaviors; nevertheless, regardless of potential improvements, the vast majority remain suboptimal across health factors. Third, our single-arm study did not measure the clinical efficacy of assessing patient-reported outcome measures itself; randomized controlled trials are required to estimate risk reduction efficacy.

Conclusions

A very small fraction of patients cared for by cardiovascular and cerebrovascular specialists at a large academic medical center are optimal for the AHA's LS7. Systematic collection of patient-reported outcome measures to refine cardiovascular disease risk, communicate prevention strategies, and promote proactive cardiovascular disease prevention within a health system is feasible to address persistent large gaps in modifiable cardiovascular disease risk.

PROMs in Cardiovascular Disease Prevention

Figures

Fig 1. Distribution of ideal Life's Simple 7 factors in patients cared for by cardiovascular or cerebrovascular specialists. Of the patients surveyed, ideal status was tabulated for each LS7 factor. A maximum score of 7 indicates ideal status across all factors. The distribution of this score across all surveyed patients is depicted.

^aAHA = American Heart Association; LS7 = Life's Simple 7

PROMs in Cardiovascular Disease Prevention

Fig 2. Proportion of patients with suboptimal LS7 factors by the presence of atherosclerotic cardiovascular disease. For each LS7 factor, the proportions of patients not ideal by ASCVD presence are depicted. Factors with at least nominally significant associations (P value < 0.05) are indicated with asterisks in the plot.

ASCVD = atherosclerotic cardiovascular disease; BMI = body mass index; Glu = glucose; LDL-C = low-density lipoprotein cholesterol

PROMs in Cardiovascular Disease Prevention

1 Tables

2 Table 1. Baseline characteristics

3

Characteristic	Value
	N = 5,950
Age (years)	64 ($\pm$ 15)
Female	2,613 (43.9%)
American Indian	10 (0.2%)
Asian	190 (3.2%)
Black	151 (2.5%)
Hispanic	202 (3.4%)
Pacific Islander	3 (0.05%)
White	4,836 (81.3%)
Recent smoker	389 (6.5%)
Diabetes	1,079 (18.1%)
ASCVD	3,478 (58.4%)
Coronary artery disease	1,598 (26.9%)
Peripheral arterial disease	1,443 (24.2%)
Myocardial infarction	911 (15.3%)
Stroke/TIA	1,178 (19.8%)
Congestive heart failure	322 (5.4%)
Atrial fibrillation	808 (13.6%)
Congenital heart disease	389 (6.5%)
Cardiology clinic	3,618 (60.8%)

PROMs in Cardiovascular Disease Prevention

Stroke clinic	902 (15.2%)
Vascular surgery	1430 (24.0%)
LS7 question survey completion	2,526 (42.4%)

Categorical variables are presented as n (%) and continuous as mean (sd).

ASCVD = atherosclerotic cardiovascular disease; LS7 = Life's Simple 7; TIA = transient ischemic attack

Table 2: Percent of patients ideal, intermediate, and poor for each LS7 factor

LS7 Factor	Ideal	Intermediate	Poor
Diet	1321 (22.2)	1911 (32.1)	2439 (41.0)
Physical activity	2776 (46.7)	1132 (19.0)	1775 (29.8)
Smoking	5076 (85.3)	224 (3.8)	389 (6.5)
LDL cholesterol	1996 (33.5)	976 (16.4)	233 (3.9)
Blood pressure	1554 (26.1)	2550 (42.9)	296 (5.0)
Glucose	1940 (32.6)	967 (16.3)	679 (11.4)
BMI	1999 (33.6)	1836 (30.9)	1567 (26.3)

^aBMI = body-mass index; LDL = low-density lipoprotein; LS7 = Life's Simple 7

Table 3. Tobacco cessation readiness indices of self-reported recent smokers

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

PROMs in Cardiovascular Disease Prevention

State of Change

Total scored	287(/289)
Pre-contemplation	101 (35.2%)
Contemplation	69 (24.0%)
Preparation	54 (18.8%)
Action	26 (9.1%)
Maintenance	37 (12.9%)

Interest Scale

Total scored	175 (/289)
0	33 (18.9%)
2	12 (6.9%)
4	11 (6.3%)
6	8 (4.6%)
8	16 (9.1%)
10	95 (54.3%)

Confidence Scale

Total scored	139(/289)
0	17 (12.2%)
2	19 (13.7%)
4	15 (10.8%)
6	19 (13.7%)
8	38 (27.3%)
10	31 (22.3%)

1

2 Variables are presented as n (%)

3

PROMs in Cardiovascular Disease Prevention

Table 4. Patients with ASCVD not taking a statin or antiplatelet or both

Statin alone	256 (29.5%)
Aspirin/clopidogrel alone	381 (43.9%)
Both statin and aspirin/clopidogrel	197 (22.7%)
Total	834
Physician, Pharmacy or Patient contacted	439 (50.6%)
Intolerance documented	148 (17.0%)
Aspirin contraindicated	16 (1.8%)
Statin contraindicated	10 (1.1%)
Taking a different antiplatelet	145 (16.7%)
Started medication at office visit	51 (5.9%)
Self-Reported Non-adherence	84 (9.7%)
Knowledge deficit	370 (42.6%)
No history of ASCVD	290 (33.4%)
Successfully reconciled or contraindicated	559 (64.4%)

*Total patients with ASCVD not taking a statin or aspirin or Plavix (or both) was 868; 834 were confirmed by the risk factor nurse

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

PROMs in Cardiovascular Disease Prevention

1 **Acknowledgements**

- 2 We wish to thank the patients and clinical providers who participated in this quality
- 3 improvement initiative at the Massachusetts General Hospital.

PROMs in Cardiovascular Disease Prevention

1 **Disclosures**

- 2 P.N. reports consulting income from Apple and research grants from Boston Scientific, Amgen,
- 3 and Apple. All other co-authors do not report any relevant conflicts of interests.

References

1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Council on E, Prevention Statistics C, Stroke Statistics S. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. *Circulation* 2018;137:e67-e492.
2. Xu J, Murphy SL, Kochanek KD, Bastian B, Arias E. Deaths: Final Data for 2016. *Natl Vital Stat Rep* 2018;67:1-76.
3. Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390:1151-1210.
4. Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, Hamavid H, Horst C, Johnson EK, Joseph J, Lavado R, Lomsadze L, Reynolds A, Squires E, Campbell M, DeCenso B, Dicker D, Flaxman AD, Gabert R, Highfill T, Naghavi M, Nightingale N, Templin T, Tobias MI, Vos T, Murray CJ. US Spending on Personal Health Care and Public Health, 1996-2013. *Jama* 2016;316:2627-2646.
5. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA,

PROMs in Cardiovascular Disease Prevention

- 1 Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD, American Heart
- 2 Association Strategic Planning Task F, Statistics C. Defining and setting national goals for
- 3 cardiovascular health promotion and disease reduction: the American Heart Association's
- 4 strategic Impact Goal through 2020 and beyond. *Circulation* 2010;121:586-613.
- 5 **6.** Ogunmoroti O, Allen NB, Cushman M, Michos ED, Rundek T, Rana JS, Blankstein R,
- 6 Blumenthal RS, Blaha MJ, Veledar E, Nasir K. Association Between Life's Simple 7 and
- 7 Noncardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis. *J Am Heart Assoc*
- 8 2016;5.
- 9 **7.** Djousse L, Petrone AB, Blackshear C, Griswold M, Harman JL, Clark CR, Talegawkar S,
- 10 Hickson DA, Gaziano JM, Dubbert PM, Correa A, Tucker KL, Taylor HA. Prevalence and
- 11 changes over time of ideal cardiovascular health metrics among African-Americans: the Jackson
- 12 Heart Study. *Preventive medicine* 2015;74:111-116.
- 13 **8.** Olson NC, Cushman M, Judd SE, McClure LA, Lakoski SG, Folsom AR, Safford MM, Zakai
- 14 NA. American Heart Association's Life's Simple 7 and risk of venous thromboembolism: the
- 15 Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. *J Am Heart Assoc*
- 16 2015;4:e001494.
- 17 **9.** Gonzalez HM, Tarraf W, Rodriguez CJ, Gallo LC, Sacco RL, Talavera GA, Heiss G, Kizer
- 18 JR, Hernandez R, Davis S, Schneiderman N, Daviglus ML, Kaplan RC. Cardiovascular health
- 19 among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos
- 20 (HCHS/SOL) results. *Am Heart J* 2016;176:134-144.
- 21 **10.** Nguyen XT, Quaden RM, Wolfrum S, Song RJ, Yan JQ, Gagnon DR, Wilson PWF, Cho K,
- 22 O'Donnell C, Gaziano JM, Djousse L, Program VAMV. Prevalence of Ideal Cardiovascular
- 23 Health Metrics in the Million Veteran Program. *Am J Cardiol* 2018;122:347-352.

PROMs in Cardiovascular Disease Prevention

- 1 **11.** Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, Gillespie C, Merritt R,
2 Hu FB. Trends in cardiovascular health metrics and associations with all-cause and CVD
3 mortality among US adults. *Jama* 2012;307:1273-1283.
- 4 **12.** Yu E, Malik VS, Hu FB. Cardiovascular Disease Prevention by Diet Modification: JACC
5 Health Promotion Series. *Journal of the American College of Cardiology* 2018;72:914-926.
- 6 **13.** Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg
7 AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Jr.,
8 Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL,
9 Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs
10 RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Jr., Tomaselli GF, American
11 College of Cardiology/American Heart Association Task Force on Practice G. 2013 ACC/AHA
12 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in
13 adults: a report of the American College of Cardiology/American Heart Association Task Force
14 on Practice Guidelines. *Circulation* 2014;129:S1-45.
- 15 **14.** Blumenthal DM, Strom JB, Valsdottir LR, Howard SE, Wagle NW, Ho KKL, Horn DM,
16 O'Keefe SM, Wasfy JH, Metlay JP, Yeh RW. Patient-Reported Outcomes in Cardiology. *Circ*
17 *Cardiovasc Qual Outcomes* 2018;11:e004794.
- 18 **15.** Akesson A, Larsson SC, Discacciati A, Wolk A. Low-risk diet and lifestyle habits in the
19 primary prevention of myocardial infarction in men: a population-based prospective cohort
20 study. *Journal of the American College of Cardiology* 2014;64:1299-1306.
- 21 **16.** Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary
22 heart disease in women through diet and lifestyle. *The New England journal of medicine*
23 2000;343:16-22.

PROMs in Cardiovascular Disease Prevention

- 1 **17.** Younus A, Aneni EC, Spatz ES, Osondu CU, Roberson L, Ogunmoroti O, Malik R, Ali SS,
2 Aziz M, Feldman T, Virani SS, Maziak W, Agatston AS, Veledar E, Nasir K. A Systematic
3 Review of the Prevalence and Outcomes of Ideal Cardiovascular Health in US and Non-US
4 Populations. *Mayo Clinic proceedings* 2016;91:649-670.
- 5 **18.** Miller WR, Rollnick, S. Motivational Interviewing: Preparing People for Change. New York:
6 Guilford Press, 2002.
- 7 **19.** Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. *Am J*
8 *Health Promot* 1997;12:38-48.
- 9 **20.** Prochaska JO, Velicer WF, Rossi JS, Goldstein MG, Marcus BH, Rakowski W, Fiore C,
10 Harlow LL, Redding CA, Rosenbloom D, et al. Stages of change and decisional balance for 12
11 problem behaviors. *Health Psychol* 1994;13:39-46.
- 12 **21.** Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P,
13 Varigos J, Lisheng L, Investigators IS. Effect of potentially modifiable risk factors associated
14 with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*
15 2004;364:937-952.
- 16 **22.** Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM,
17 Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC, Jr., Svetkey LP,
18 Wadden TA, Yanovski SZ, Kendall KA, Morgan LC, Trisolini MG, Velasco G, Wnek J,
19 Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman
20 JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Jr., Tomaselli GF,
21 American College of Cardiology/American Heart Association Task Force on Practice G. 2013
22 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the

PROMs in Cardiovascular Disease Prevention

- 1 American College of Cardiology/American Heart Association Task Force on Practice
- 2 Guidelines. *Circulation* 2014;129:S76-99.
- 3 **23.** Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF,
- 4 Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, Committee FS, Investigators.
- 5 Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *The New England*
- 6 *journal of medicine* 2017;376:1713-1722.
- 7 **24.** Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman
- 8 SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R,
- 9 Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, Committees OO,
- 10 Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *The*
- 11 *New England journal of medicine* 2018;379:2097-2107.
- 12 **25.** Usher-Smith JA, Silarova B, Schuit E, Moons KG, Griffin SJ. Impact of provision of
- 13 cardiovascular disease risk estimates to healthcare professionals and patients: a systematic
- 14 review. *BMJ Open* 2015;5:e008717.
- 15 **26.** Benner JS, Erhardt L, Flammer M, Moller RA, Rajcic N, Changela K, Yunis C, Cherry SB,
- 16 Gaciong Z, Johnson ES, Sturkenboom MC, Garcia-Puig J, Girerd X, Investigators RO. A novel
- 17 programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and
- 18 improves patients' modifiable risk factor profile. *Int J Clin Pract* 2008;62:1484-1498.
- 19 **27.** Deshpande S, Quek RG, Forbes CA, de Kock S, Kleijnen J, Gandra SR, Simpson RJ, Jr. A
- 20 systematic review to assess adherence and persistence with statins. *Curr Med Res Opin*
- 21 2017;33:769-778.
- 22 **28.** Vonbank A, Agewall S, Kjeldsen KP, Lewis BS, Torp-Pedersen C, Ceconi C, Funck-
- 23 Brentano C, Kaski JC, Niessner A, Tamargo J, Walther T, Wassmann S, Rosano G, Schmidt H,

PROMs in Cardiovascular Disease Prevention

- 1 Saely CH, Drexel H. Comprehensive efforts to increase adherence to statin therapy. *Eur Heart J*
- 2 2017;38:2473-2479.
- 3 **29.** Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of
- 4 Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. *JAMA*
- 5 *Cardiol* 2019.
- 6 **30.** van Driel ML, Morledge MD, Ulep R, Shaffer JP, Davies P, Deichmann R. Interventions to
- 7 improve adherence to lipid-lowering medication. *Cochrane Database Syst Rev*
- 8 2016;12:CD004371.
- 9 **31.** Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation.
- 10 *Cochrane Database Syst Rev* 2005:CD001007.
- 11 **32.** Coleman T. ABC of smoking cessation. Use of simple advice and behavioural support. *BMJ*
- 12 2004;328:397-399.
- 13 **33.** Borland R, Balmford J, Bishop N, Segar C, Piterman L, McKay-Brown L, Kirby C, Tasker
- 14 C. In-practice management versus quitline referral for enhancing smoking cessation in general
- 15 practice: a cluster randomized trial. *Fam Pract* 2008;25:382-389.
- 16 **34.** Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking
- 17 cessation. *Cochrane Database Syst Rev* 2013:CD002850.
- 18 **35.** Daly J, Sindone AP, Thompson DR, Hancock K, Chang E, Davidson P. Barriers to
- 19 participation in and adherence to cardiac rehabilitation programs: a critical literature review.
- 20 *Prog Cardiovasc Nurs* 2002;17:8-17.
- 21 **36.** Moore SM, Dolansky MA, Ruland CM, Pashkow FJ, Blackburn GG. Predictors of women's
- 22 exercise maintenance after cardiac rehabilitation. *J Cardiopulm Rehabil* 2003;23:40-49.